Europe Cardiac Biomarkers Market Size & Outlook, 2024-2030
Europe cardiac biomarkers market, 2018-2030 (US$M)
Europe cardiac biomarkers market highlights
- The Europe cardiac biomarkers market generated a revenue of USD 5,534.1 million in 2024.
- The market is expected to grow at a CAGR of 13.3% from 2025 to 2030.
- In terms of segment, troponin was the largest revenue generating type in 2024.
- Troponin is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2025 to 2030.
Europe data book summary
| Market revenue in 2024 | USD 5,534.1 million |
| Market revenue in 2030 | USD 11,658.9 million |
| Growth rate | 13.3% (CAGR from 2025 to 2030) |
| Largest segment | Troponin |
| Fastest growing segment | Troponin |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Troponin, CK-MB, Myoglobin, BNP and NT-proBNP |
| Key market players worldwide | Abbott Laboratories, QuidelOrtho Corp, Siemens Healthineers AG ADR, Roche Holding AG ADR, Danaher Corp, BioMerieux SA, Bio-Rad Laboratories Inc, Randox, Creative Diagnostics, Life Diagnostics |
Other key industry trends
- In terms of revenue, Europe region accounted for 23.8% of the global cardiac biomarkers market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 12,541.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cardiac Biomarkers Market Scope
Cardiac Biomarkers Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe cardiac biomarkers market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cardiac biomarkers market will help companies and investors design strategic landscapes.
Troponin was the largest segment with a revenue share of 40.5% in 2024. Horizon Databook has segmented the Europe cardiac biomarkers market based on troponin, ck-mb, myoglobin, bnp and nt-probnp covering the revenue growth of each sub-segment from 2018 to 2030.
Europe has reported CVDs as the leading cause of death among the European population as compared to other diseases. The risk burden of CHD and heart attack is the maximum in the European region.
One of the prime risk factors of heart diseases is high blood pressure, which is a high concern within Europe, as a result, the healthcare priority of the region centers on its diagnosis, treatment, and control. In an effort to cut down healthcare spending, healthcare regulatory bodies in the EU are increasingly focused toward curbing the economic burden stemming from the high incidence of CVDs.
Germany largely focuses on R&D and new product innovation in diagnostics. For instance, Roche invested 240 million Swiss in 2012 to set up the production of diagnostics in Germany. Healthcare spending in Germany, which is 11.3 % of the total GDP, is allocated for the development of the healthcare infrastructure. on
Reasons to subscribe to Europe cardiac biomarkers market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe cardiac biomarkers market databook
-
Our clientele includes a mix of cardiac biomarkers market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe cardiac biomarkers market , including forecasts for subscribers. This continent databook contains high-level insights into Europe cardiac biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe cardiac biomarker market size, by country, 2018-2030 (US$M)
Europe Cardiac Biomarkers Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
